Author:
Gallo Ester,Mingozzi Silvia,Mella Alberto,Fop Fabrizio,Presta Roberto,Burdese Manuel,Boaglio Elena,Torazza Maria Cristina,Giraudi Roberta,Leonardi Gianluca,Lavacca Antonio,Gontero Paolo,Sedigh Omidreza,Bosio Andrea,Verri Aldo,Dolla Caterina,Biancone Luigi
Abstract
Abstract
Background
Rare diseases (RDs) encompass many difficult-to-treat conditions with different characteristics often associated with end-stage renal disease (ESRD). However, data about transplant outcomes in adult patients are still lacking and limited to case reports/case series without differentiation between immunological/non-immunological RDs.
Methods
Retrospective analysis among all adult kidney transplanted patients (KTs) with RDs (RDsKT group) performed in our high-volume transplantation center between 2005 and 2016. RDs were classified according to the Orphanet code system differentiating between immunological and non-immunological diseases, also comparing clinical outcomes and temporal trends to a control population without RDs (nRDsKT).
Results
Among 1381 KTs, 350 patients (25.3%) were affected by RDs (RDsKTs). During a f/up > 5 years [median 7.9 years (4.8–11.1)], kidney function and graft/patient survival did not differ from nRDsKTs. Considering all post-transplant complications, RDsKTs (including, by definition, patients with primary glomerulopathy except on IgA nephropathy) have more recurrent and de-novo glomerulonephritis (14.6% vs. 9.6% in nRDsKTs; p = 0.05), similar rates of de-novo cancers, post-transplant diabetes, dysmetabolism, hematologic disorders, urologic/vascular problems, and lower infectious episodes than nRDsKTs (63.7% vs 72.7%; p = 0.013). Additional stratification for immunological and non-immunological RDsKTs or transplantation periods (before/after 2010) showed no differences or temporal trends between groups.
Conclusions
Kidney transplant centers are deeply involved in RDs management. Despite their high-complex profile, both immunological and non-immunological RDsKTs experienced favorable patients’ and graft survival.
Publisher
Springer Science and Business Media LLC
Reference28 articles.
1. Commission of the European Community: COMMUNICATION FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT, THE COUNCIL, THE EUROPEAN ECONOMIC AND SOCIAL COMMITTEE AND THE COMMITTEE OF THE REGIONS on Rare Diseases: Europe’s challenges. Available at: https://ec.europa.eu/health/ph_threats/non_com/docs/rare_com_en.pdf, Aug 17 2020.
2. Piano nazionale Malattie rare, Italian Health Department. Available at: http://www.salute.gov.it/portale/temi/p2_6.jsp?lingua=italiano&id=3296&area=Malattie%20rare&menu=vuoto , Jul 08 2020.
3. Wühl E, Van Stralen KJ, Wanner C, Ariceta G, Heaf JG, Bjerre AK, et al. Renal replacement therapy for rare diseases affecting the kidney: An analysis of the ERA-EDTA Registry. Nephrol Dial Transplant. 2014;29:iv1–8.
4. Forman J, Taruscio D, Llera VA, Barrera LA, Coté TR, Edfjäll C, et al. The need for worldwide policy and action plans for rare diseases. Acta Paediatr Int J Paediatr. 2012;101:805–7.
5. Aymé S, Bockenhauer D, Day S, Devuyst O, Guay-Woodford LM, Ingelfinger JR, et al. Common elements in rare kidney diseases: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int. 2017;92:796–808.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献